๐ ็ธฝ็ฎ้ ๏ฝ ๐ ่ฑๆๅๆ๏ผๆฌ็ฏ๏ผ ๏ฝ ๐ ๅฎๆด็ฟป่ญฏ ๏ฝ โญ ็ฒพ่ฏ็ญ่จ
HISTORY
The first successful allogeneic bone marrow transplant was performed in 1968. Subsequent advances in histocompatibility antigen testing increased safety, while establishment of bone marrow donor registries made HSCT accessible to thousands of patients each year who lacked a matched related donor. The introduction of alternative stem cell sources, including matched unrelated donors and especially haploidentical family donors, has led to a further increase in the number of transplants. In addition, when neither of these donor sources is available, umbilical cord stem cells represent a more universal option because a greater degree of mismatch is better tolerated. The evolution of reduced intensity conditioning regimens has permitted older patients and those with comorbidities to receive HSCTs. Post-transplant cyclophosphamide, initially introduced for haploidentical HSCTs, is increasingly being used for matched sibling and matched unrelated donor (MUD) HSCTs where it has significantly reduced the incidence and severity of acute and chronic GVHD.